{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:55:38Z","timestamp":1792108538544,"version":"4.4.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1053\/j.seminhematol.2019.11.004","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T11:28:42Z","timestamp":1573644522000},"page":"229-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Ensuring safety of the blood supply in the United States: Donor screening, testing, emerging pathogens, and pathogen inactivation"],"prefix":"10.1053","volume":"56","author":[{"given":"Elizabeth A.","family":"Godbey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Thibodeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2019.11.004_bib0001","unstructured":"Blood Guidances. https:\/\/www.fda.gov\/vaccines-blood-biologics\/biologics-guidances\/blood-guidances. Food and Drug Administration. Content Current as of June 13, 2019. Last accessed July 8, 2019. In:Services USDoHaH, editor."},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0002","unstructured":"Ooley, P, ed. Standards for Blood Banks and Transfusion Services, 31st ed. AABB, Bethesda, MD, 2018."},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0003","unstructured":"College of American Pathologists, Commission on Laboratory Accreditation. Transfusion Medicine Checklist. September 17, 2019 ed. Northfield, Il: College of American Pathologists; 2019."},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0004","unstructured":"AABB Donor History Task Force, Blood donor educational material, version 2.0. Bethesda, MD: AABB, 2016. http:\/\/www.aabb.org\/tm\/questionnaires\/Pages\/dhqaabb.aspx, accessed November 18, 2019."},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0005","unstructured":"AABB Donor History Task Force, Medication deferral list, version 2.0. Bethesda, MD: AABB, 2016. http:\/\/www.aabb.org\/tm\/questionnaires\/Pages\/dhqaabb.aspx, accessed November 18, 2019."},{"issue":"11","key":"10.1053\/j.seminhematol.2019.11.004_bib0006","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1111\/j.1537-2995.2007.01422.x","article-title":"Implementation of the Uniform Donor History Questionnaire across the American Red Cross Blood Services: increased deferral among repeat presenters but no measurable impact on blood safety","volume":"47","author":"Zou","year":"2007","journal-title":"Transfusion"},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0007","unstructured":"Food and Drug Administration. Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma Guidance for Industry, July 2016. Docket No. FDA-2011-D-0722. Center for Biologics Evaluation and Research. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/implementation-acceptable-full-length-and-abbreviated-donor-history-questionnaires-and-accompanying. Content current as of April 30, 2019. Last accessed November 18, 2019."},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0008","unstructured":"AABB Donor History Task Force, Full-length blood donor history questionnaire, version 2.0. Bethesda, MD: AABB, 2016. http:\/\/www.aabb.org\/tm\/questionnaires\/Pages\/dhqaabb.aspx, accessed November 18, 2019."},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0009","unstructured":"AABB Donor History Task Force, Blood donor history questionaires. Bethesda, MD: AABB, 2016. http:\/\/www.aabb.org\/tm\/questionnaires\/Pages\/dhqaabb.aspx, accessed November 18, 2019."},{"issue":"4","key":"10.1053\/j.seminhematol.2019.11.004_bib0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000330474","article-title":"Interventions implemented to reduce the risk of transmission of bacteria by transfusion in the English National Blood Service","volume":"38","author":"McDonald","year":"2011","journal-title":"Transfus Med Hemother"},{"issue":"3","key":"10.1053\/j.seminhematol.2019.11.004_bib0011","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.0042-9007.2004.00404.x","article-title":"Relative values of the interventions of diversion and improved donor-arm disinfection to reduce the bacterial risk from blood transfusion","volume":"86","author":"McDonald","year":"2004","journal-title":"Vox Sanguinis"},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0012","unstructured":"Food and Drug Administration. Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry, Guidance for Industry, December 2017. FDA-2005-D-0140. Center for Biologics Evaluation and Research. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/nucleic-acid-testing-nat-human-immunodeficiency-virus-type-1-hiv-1-and-hepatitis-c-virus-hcv-testing. Content current as of April 30, 2019. Last accessed November 18, 2019."},{"issue":"1","key":"10.1053\/j.seminhematol.2019.11.004_bib0013","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1537-2995.1969.tb04909.x","article-title":"Transmission of syphilis by fresh blood components","volume":"9","author":"Chambers","year":"1969","journal-title":"Transfusion"},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0014","unstructured":"Food and Drug Administration. Recommendations for Screening,Testing, and Management of Blood Donors and Blood and Blood Components Based on Screening Tests for Syphilis, Guidance for Industry, September 2014. Docket No. FDA-2003-D-0128, Center for Biologics Evaluation and Research. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/recommendations-screening-testing-and-management-blood-donors-and-blood-and-blood-components-based. Content current as of May 15, 2019. Last accessed November 18, 2019."},{"issue":"4","key":"10.1053\/j.seminhematol.2019.11.004_bib0015","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2015-07-655944","article-title":"Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance","volume":"127","author":"Hong","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0016","unstructured":"Food and Drug Administration, Blood Products Advisory Committee meeting, FDA White Oak Campus, Silver Spring, MD. July 18-19, 2019. https:\/\/www.fda.gov\/advisory-committees\/blood-products-advisory-committee\/2018-meeting-materials-blood-products-advisory-committee. Accessed on November 18, 2019."},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0017","unstructured":"Food and Drug Administration. Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion, Guidance for Industry, December 2018. Docket No. FDA-2014-D-1814. Center for Biologics Evaluation and Research. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bacterial-risk-control-strategies-blood-collection-establishments-and-transfusion-services-enhance. Content current as of September 30, 2019. Last accessed November 18, 2019."},{"issue":"9","key":"10.1053\/j.seminhematol.2019.11.004_bib0018","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1111\/trf.15410","article-title":"Toward universal pathogen reduction of the blood supply","volume":"59","author":"Marks","year":"2019","journal-title":"Transfusion"},{"issue":"3","key":"10.1053\/j.seminhematol.2019.11.004_bib0019","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/tme.12298","article-title":"Quality of red cells after combination of prion reduction and treatment with the intercept system for pathogen inactivation","volume":"26","author":"Wiltshire","year":"2016","journal-title":"Transfus Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2019.11.004_bib0020","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1111\/trf.15317","article-title":"The BEST criteria improve sensitivity for detecting positive cultures in residual blood components cultured in suspected septic transfusion reactions","volume":"59","author":"Shih","year":"2019","journal-title":"Transfusion"},{"issue":"11","key":"10.1053\/j.seminhematol.2019.11.004_bib0021","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1111\/trf.13759","article-title":"Development of a multisystem surveillance database for transfusion-transmitted infections among blood donors in the United States","volume":"56","author":"Dodd","year":"2016","journal-title":"Transfusion"},{"issue":"50","key":"10.1053\/j.seminhematol.2019.11.004_bib0022","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1537-2995.2010.02728.x","article-title":"Progress in monitoring blood safety","volume":"50","author":"Epstein","year":"2010","journal-title":"Transfusion"},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0023","unstructured":"Dodd RY.Landscape of infectious disease risks. Presented September 13, 2018. Athttps:\/\/www.hhs.gov\/oidp\/advisory-committee\/blood-tissue-safety-availability\/meetings\/2018-09-13\/index.html. Last accessed July 19, 2019."},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0024","series-title":"Division of viral hepatitis, National Center for HIV\/AIDS, viral hepatitis, STD, and TB prevention","year":"2016"},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0025","unstructured":"Food and Drug Administration. Use of Nucleic Acid Tests on Pooled and Individual Samples From Donors of Whole Blood and Blood Components, Including Source Plasma, to Reduce the Risk of Transmission of Hepatitis B Virus, Final Guidance for Industry, October 2012. Docket No. FDA-2011-D-0799, Center for Biologics Evaluation and Research. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-nucleic-acid-tests-reduce-risk-transmission-hepatitis-b-virus-donors-human-cells-tissues-and. Content current as of May 17, 2019. Last accessed November 18, 2019."},{"issue":"2","key":"10.1053\/j.seminhematol.2019.11.004_bib0026","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tmrv.2019.01.001","article-title":"Transfusion-transmitted infections reported to the National Healthcare Safety Network Hemovigilance module","volume":"33","author":"Haass","year":"2019","journal-title":"Transfus Med Rev"},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0027","unstructured":"Food and Drug Administration. Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products, Guidance for Industry, December 2015. Docket No. FDA-2015-D-1211. Center for Biologics Evaluation and Research. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/revised-recommendations-reducing-risk-human-immunodeficiency-virus-transmission-blood-and-blood. Content current as of November 18, 2018. Last accessed November 18, 2019."},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0028","unstructured":"Guidance for Industry donor screening for antibodies to HTLV-II, 1997. FDA-2013-S-0610. Center for Biologics Evaluation and Research (CBER), Food and Drug Administration. Content current as of May 15, 2019. Last accessed July 7, 2019. In: Services USDoHaH, editor."},{"issue":"8","key":"10.1053\/j.seminhematol.2019.11.004_bib0029","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/vox.12722","article-title":"Human T-cell lymphotropic virus: a simulation model to estimate residual risk with universal leucoreduction and testing strategies in Canada","volume":"113","author":"O'Brien","year":"2018","journal-title":"Vox Sang"},{"issue":"2","key":"10.1053\/j.seminhematol.2019.11.004_bib0030","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3201\/eid2502.180765","article-title":"Cumulative incidence of West Nile Virus infection, continental United States, 1999-2016","volume":"25","author":"Ronca","year":"2019","journal-title":"Emerg Infect Dis"},{"issue":"13","key":"10.1053\/j.seminhematol.2019.11.004_bib0031","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJMoa030969","article-title":"Transmission of West Nile Virus through blood transfusion in the United States in 2002","volume":"349","author":"Pealer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0032","unstructured":"Food and Drug Administration. Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Donors of Whole Blood and Blood Components Intended for Transfusion, Guidance for Industry; November 2009. Docket No. FDA-2008-D-0263. Center for Biologics Evaluation and Research. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-nucleic-acid-tests-reduce-risk-transmission-west-nile-virus-donors-whole-blood-and-blood. Content current as of May 01, 2019. Last accessed November 18, 2019."},{"issue":"3pt2","key":"10.1053\/j.seminhematol.2019.11.004_bib0033","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/trf.14018","article-title":"A probable case of West Nile virus transfusion transmission","volume":"57","author":"Groves","year":"2017","journal-title":"Transfusion"},{"issue":"3pt2","key":"10.1053\/j.seminhematol.2019.11.004_bib0034","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/trf.14028","article-title":"Zika virus and blood transfusion: the experience of French Polynesia","volume":"57","author":"Bierlaire","year":"2017","journal-title":"Transfusion"},{"issue":"19","key":"10.1053\/j.seminhematol.2019.11.004_bib0035","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa1714977","article-title":"Investigational testing for Zika virus among U.S. blood donors","volume":"378","author":"Sa\u00e1","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0036","unstructured":"Food and Drug Administration. Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components, Guidance for Industry, July 2018. Docket No. FDA-2016-D-0545. Center for Biologics Evaluation and Research. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/revised-recommendations-reducing-risk-zika-virus-transmission-blood-and-blood-components. Content current as of July 08, 2018. Last accessed November 18, 2019."},{"issue":"Suppl 2","key":"10.1053\/j.seminhematol.2019.11.004_bib0037","first-page":"1S","article-title":"Emerging infectious disease agents and their potential threat to transfusion safety","volume":"49","author":"Stramer","year":"2009","journal-title":"Transfusion"},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0038","unstructured":"Food and Drug Administration. Nucleic Acid Testing (NAT) to Reduce the Possible Risk of Human Parvovirus B19 Transmission by Plasma-Derived Products, Guidance for industry, July 2009. Docket No. FDA-2008-D-0379. Center for Biologics Evaluation and Research. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/nucleic-acid-testing-reduce-possible-risk-parvovirus-b19-transmission-plasma-derived-products. Content current as of May 15, 2019. Last accessed November 18, 2019."},{"issue":"12","key":"10.1053\/j.seminhematol.2019.11.004_bib0039","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.5858\/arpa.2016-0461-OA","article-title":"Survey on transfusion-transmitted cytomegalovirus and cytomegalovirus disease mitigation","volume":"141","author":"Weisberg","year":"2017","journal-title":"Arch Pathol Lab Med"},{"issue":"6 Pt 2","key":"10.1053\/j.seminhematol.2019.11.004_bib0040","first-page":"1581","article-title":"AABB committee report: reducing transfusion-transmitted cytomegalovirus infections","volume":"56","author":"Aabb","year":"2016","journal-title":"Transfusion"},{"issue":"1","key":"10.1053\/j.seminhematol.2019.11.004_bib0041","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/vox.12727","article-title":"International survey on the impact of parasitic infections: frequency of transmission and current mitigation strategies","volume":"114","author":"Leiby","year":"2019","journal-title":"Vox Sang"},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0042","unstructured":"Food and Drug Administration. Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Blood and Blood Components, Guidance for Industry, December 2017. Docket No. FDA-2009-D-0137. Center for Biologics Evaluation and Research. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-serological-tests-reduce-risk-transmission-trypanosoma-cruzi-infection-blood-and-blood. Content current as of November 15, 2018. Last accessed November 18, 2019."},{"issue":"3","key":"10.1053\/j.seminhematol.2019.11.004_bib0043","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/trf.15118","article-title":"Impact of one-time testing for Trypanosoma cruzi antibodies among blood donors in the United States","volume":"59","author":"Dodd","year":"2019","journal-title":"Transfusion"},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0044","series-title":"Screening blood donors with the donor history questionnaire","article-title":"Travel and related health history: malaria, prions, and other transfusion-transmissible diseases","author":"Katz","year":"2019"},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0045","unstructured":"Food and Drug Administration. Recommendations for Donor Questioning, Deferral, Reentry and Product Management to Reduce the Risk of Transfusion-Transmitted Malaria, Guidance for Industry. Docket No. FDA-2000-D-0187. Center for Biologics Evaluation and Research. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/recommendations-donor-questioning-deferral-reentry-and-product-management-reduce-risk-transfusion. Content current as of May 15, 2019. Last accessed November 18, 2019."},{"issue":"12","key":"10.1053\/j.seminhematol.2019.11.004_bib0046","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1111\/j.1537-2995.2009.02317.x","article-title":"Transfusion-transmitted Babesia microti identified through hemovigilance","volume":"49","author":"Tonnetti","year":"2009","journal-title":"Transfusion"},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0047","unstructured":"Food and Drug Administration. Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis, Guidance for Industry, May 2019. Docket No. FDA-2018-D-2478. Center for Biologics Evaluation and Research. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/recommendations-reducing-risk-transfusion-transmitted-babesiosis. Content current as of May 09, 2019. Last accessed November 18, 2019."},{"issue":"8","key":"10.1053\/j.seminhematol.2019.11.004_bib0048","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1111\/trf.14912","article-title":"Assessing the risk of Babesia to the United States blood supply using a risk-based decision-making approach: report of AABB's Ad Hoc Babesia Policy Working Group (original report)","volume":"58","author":"Ward","year":"2018","journal-title":"Transfusion"},{"issue":"2","key":"10.1053\/j.seminhematol.2019.11.004_bib0049","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/trf.15043","article-title":"The impact of Babesia microti blood donation screening","volume":"59","author":"Tonnetti","year":"2019","journal-title":"Transfusion"},{"issue":"1","key":"10.1053\/j.seminhematol.2019.11.004_bib0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1128\/CMR.18.1.195-204.2005","article-title":"Bacterial contamination of blood components","volume":"18","author":"Brecher","year":"2005","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"10.1053\/j.seminhematol.2019.11.004_bib0051","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1586\/ehm.11.53","article-title":"Bacterial contamination of platelet components: potential solutions to prevent transfusion-related sepsis","volume":"4","author":"Corash","year":"2011","journal-title":"Expert Rev Hematol"},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0052","unstructured":"Food and Drug Administration. Fatalities Reported to FDA Following Blood Collection and Transfusion: Annual Summary for Fiscal year 2017. https:\/\/www.fda.gov\/media\/124796\/download. Accessed November 18, 2019."},{"issue":"2","key":"10.1053\/j.seminhematol.2019.11.004_bib0053","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/trf.15008","article-title":"Evaluation of the National Healthcare Safety Network Hemovigilance Module for transfusion-related adverse reactions in the United States","volume":"59","author":"Edens","year":"2019","journal-title":"Transfusion"},{"issue":"4","key":"10.1053\/j.seminhematol.2019.11.004_bib0054","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/vox.12767","article-title":"In the NAT era, is routine lookback to recipients still required when donors seroconvert for HIV infection?","volume":"114","author":"Vishram","year":"2019","journal-title":"Vox Sang"},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0055","unstructured":"Transfusion Transmitted Diseases Committee, AABB. Fact sheets created or updated post publication of the transfusion August 2009 supplement. AABB, Bethesda, MD. http:\/\/www.aabb.org\/tm\/eid\/Pages\/eidpostpub.aspx. Accessed November 18, 2019."},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0056","unstructured":"INTERCEPT\u00ae Blood System for Platelets - Small Volume (SV) Processing Set [package insert]. Concord, CA; Cerus Corporation; 2016."},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0057","unstructured":"INTERCEPT\u00ae Blood System for Platelets - Large Volume (LV) Processing Set [package insert]. Concord, CA; Cerus Corporation; 2016."},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0058","unstructured":"INTERCEPT\u00ae Blood System for Platelets - Dual Storage (DS) Processing Set [package insert]. Concord, CA; Cerus Corporation; 2016."},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0059","unstructured":"INTERCEPT\u00ae Blood System for Plasma [package insert]. Concord, CA, Cerus Corporation; 2014."},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0060","unstructured":"INTERCEPT\u00ae Blood System for Platelets Pathogen Reduction System - overview. Cerus Corporation. https:\/\/intercept-usa.com\/images\/resources\/Product_Information\/INTERCEPT_Overview_MAY2019.pdf. Accessed November 18, 2019."},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0061","unstructured":"Implementation of pathogen reduction technology in the manufacture of blood components in blood establishments: questions and answers draft guidance for industry. Docket No. FDA-2017-D-6784. Center for Biologics Evaluation and Research, Food and Drug Administration. Content current as of November 14, 2018. Last accessed July 8, 2019. In: Services USDoHaH, editor."},{"issue":"4","key":"10.1053\/j.seminhematol.2019.11.004_bib0062","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/trf.15119","article-title":"Bacterial inactivation of platelet concentrates with the THERAFLEX UV-platelets pathogen inactivation system","volume":"59","author":"Gravemann","year":"2019","journal-title":"Transfusion"},{"issue":"11","key":"10.1053\/j.seminhematol.2019.11.004_bib0063","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1111\/trf.14256","article-title":"Reduction of Zika virus infectivity in platelet concentrates after treatment with ultraviolet C light and in plasma after treatment with methylene blue and visible light","volume":"57","author":"Fryk","year":"2017","journal-title":"Transfusion"},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0064","unstructured":"FDA summary of safety and effectiveness data\u2014INTERCEPT blood system for platelets. r_Cerus platelets SSED 12-18-14 finalclean.pdf. PMA No. BP140143; 2014."},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0065","unstructured":"Food and Drug Administration, Blood Products Advisory Committee meeting, FDA White Oak Campus, Silver Spring, MD. March 20-21, 2019. https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/blood-products-advisory-committee-march-20-21-2019-meeting-announcement-03202019-03212019#event-materials. Accessed on November 18, 2019."},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0066","unstructured":"Health Canada. Statement from the Minister of Health on further reducing barriers for blood donation by men who have sex with men. https:\/\/www.canada.ca\/en\/health-canada\/news\/2019\/05\/statement-from-the-minister-of-health-on-further-reducing-barriers-for-blood-donation-by-men-who-have-sex-with-men.html. Government of Canada May 8, 2019. Last accessed November 18, 2019."},{"key":"10.1053\/j.seminhematol.2019.11.004_bib0067","unstructured":"Food and Drug Administration. Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion, Guidance for Industry, September 2019. Docket No. FDA-2014-D-1814. Center for Biologics Evaluation and Research. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bacterial-risk-control-strategies-blood-collection-establishments-and-transfusion-services-enhance. Content current as of September 30, 2019. Last accessed November 18, 2019."}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196319300666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196319300666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:25:51Z","timestamp":1758522351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196319300666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0037196319300666"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2019.11.004","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ensuring safety of the blood supply in the United States: Donor screening, testing, emerging pathogens, and pathogen inactivation","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2019.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}